Cortina Asset Management LLC trimmed its position in Codexis, Inc. (NASDAQ:CDXS) by 21.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,042,341 shares of the biotechnology company’s stock after selling 280,063 shares during the quarter. Cortina Asset Management LLC owned 2.16% of Codexis worth $6,932,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its holdings in Codexis by 15.7% in the second quarter. Nationwide Fund Advisors now owns 21,568 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 2,928 shares during the last quarter. Bank of America Corp DE boosted its holdings in Codexis by 2.9% in the first quarter. Bank of America Corp DE now owns 25,477 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 717 shares during the last quarter. Perkins Capital Management Inc. bought a new position in Codexis in the second quarter valued at about $164,000. The Manufacturers Life Insurance Company boosted its holdings in Codexis by 30.5% during the second quarter. The Manufacturers Life Insurance Company now owns 35,264 shares of the biotechnology company’s stock worth $192,000 after buying an additional 8,244 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Codexis by 23.3% during the second quarter. Rhumbline Advisers now owns 42,872 shares of the biotechnology company’s stock worth $234,000 after buying an additional 8,095 shares during the last quarter. Hedge funds and other institutional investors own 65.71% of the company’s stock.
In other Codexis news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $5.78, for a total value of $6,126,800.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 9.80% of the company’s stock.
Codexis, Inc. (NASDAQ:CDXS) traded up $0.25 during trading on Thursday, hitting $6.85. The stock had a trading volume of 242,567 shares, compared to its average volume of 170,228. Codexis, Inc. has a 12 month low of $3.60 and a 12 month high of $7.95.
A number of equities research analysts have recently commented on CDXS shares. Zacks Investment Research raised Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Jefferies Group reissued a “buy” rating and issued a $9.00 target price (up previously from $8.00) on shares of Codexis in a research report on Monday, October 2nd. HC Wainwright reissued a “buy” rating and issued a $8.50 target price on shares of Codexis in a research report on Tuesday, November 21st. ValuEngine upgraded Codexis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub upgraded Codexis from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $7.50.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2017/12/07/cortina-asset-management-llc-has-6-93-million-holdings-in-codexis-inc-cdxs-updated-updated-updated.html.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.